Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting.

ABSTRACT: Ovarian cancer (OC) is the eighth most common cancer among the female population and the most lethal of all the female reproductive system malignancies. Poly (ADP-ribose) polymerase inhibitors (PARPis) have reshaped the treatment scenario of metastatic OC in the maintenance setting post platinum-based chemotherapy. Niraparib is the first Food and Drug Administration (FDA)- and European Medical Agency (EMA)-approved PARPi as maintenance therapy for platinum-sensitive OC, regardless of BReast CAncer gene (BRCA) status, in first-line patients, with a recent restriction to germline BRCA mutations in second-line patients. In this review, we comprehensively summarized the pharmacological properties of niraparib, alongside the efficacy and safety data of the main trials leading to the current app

SUBMITTER: Maiorano MFP 

PROVIDER: S-EPMC10536506 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature